芪苈强心胶囊对酶放大免疫法测定地高辛血药浓度的影响

目的研究患者口服芪苈强心胶囊对酶放大免疫法(EMIT)测定地高辛血药浓度的影响,为临床安全、有效、合理使用芪苈强心胶囊、地高辛以及开展相关治疗药物监测(TDM)提供参考。方法收集90例使用芪苈强心胶囊、地高辛或两者联合应用的住院患者,应用EMIT法测定血浆中地高辛浓度,进行统计分析,并建立超快速液相色谱-串联质谱(UFLC-MS/MS)测定体内地高辛药物浓度的分析方法,测定单用芪苈强心胶囊患者血浆中及芪苈强心胶囊溶液中地高辛浓度,并与EMIT法测定的结果相比较。结果 EMIT法在单用芪苈强心胶囊的患者血浆中测到地高辛阳性结果。芪苈强心胶囊联合地高辛应用组、单用芪苈强心胶囊组的EMIT法检测结果与单用地高辛组的患者相比均有升高,且差异具有统计学意义(P <0.05)。但应用UFLCMS/MS法均未从单独服用芪苈强心胶囊的患者体内及芪苈强心胶囊溶液中检测到地高辛,芪苈强心胶囊溶液的EMIT法检测结果为阳性,且结果与浓度呈线性相关。结论口服芪苈强心胶囊会对EMIT法测定地高辛血药浓度造成干扰,且影响程度可能与服用剂量相关。临床应当充分考虑芪苈强心胶囊对常规地高辛血药浓度的影响,密切关注患者的疾病进程、临床反应以及合并用药等因素,力求制订合理的个体化给药方案。     

芪苈强心胶囊联合地高辛治疗心肌梗死后心力衰竭的疗效观察

目的比较芪苈强心胶囊联合地高辛及单用地高辛治疗心肌梗死后心力衰竭的临床疗效。方法 60例患者随机分成两组。对照组30例采用常规心力衰竭治疗,即口服地高辛片半片、一日一次,同时联合应用利尿剂、ACEI/ARB或β受体阻滞剂(达最大靶计量)、阿托伐他汀等。实验组30例在对照组基础上加口服芪苈强心胶囊4粒、一日三次。两组疗程均为4周。结果实验组和对照组总有效率分别为93.9%与81.7%。两组比较差异有显著性意义(P<0.05)。结论芪苈强心胶囊联合地高辛治疗心肌梗死后心力衰竭患者疗效较好。     

芪苈强心胶囊与辅酶Q_(10)胶囊联合治疗扩张型心肌病60例

目的观察芪苈强心胶囊与辅酶Q10胶囊联合治疗扩张型心肌病的疗效。方法将60例患者随机分为两组:治疗组与对照组各30例。对照组给予强心、利尿、扩血管及营养心肌等常规综合治疗,治疗组在常规治疗基础上给予芪苈强心胶囊(4粒,3次/d),辅酶Q10(10mg,3次/d),14d为1个疗程,观察比较两组的疗效、结果。结果治疗组患者总有效率明显高于对照组,差异有统计学意义(P<0.01)。结论芪苈强心胶囊与辅酶Q10胶囊联合治疗扩张型心肌病具有疗效显著、疗程短、不良反应小等特点,值得临床推广应用。     

芪苈强心胶囊联合瑞舒伐他汀治疗急性心肌梗死的临床研究

目的 探讨芪苈强心胶囊联合瑞舒伐他汀钙片治疗急性心肌梗死的临床疗效.方法 选取2018年2月—2020年8月洛阳石化医院收治的76例急性心肌梗死患者,根据随机数字表法将所有患者分为对照组和治疗组,每组各38例.对照组口服瑞舒伐他汀钙片,10 mg/次,1次/d.治疗组在对照组的基础上口服芪苈强心胶囊,4粒/次,3次/d...     

芪苈强心胶囊结合西药治疗慢性心力衰竭的临床观察

目的探讨芪苈强心胶囊联合西药治疗慢性心力衰竭（CHF）的临床效果。方法将CHF患者72例随机分为治疗组和对照组各36例,对照组给予螺内酯片、地高辛片、马来酸依那普利片,以及饮食、运动锻炼等一般治疗。治疗组在对照组治疗基础上应用芪苈强心胶囊。观察2组临床治疗效果,以及左室射血分数（LVEF）、心脏指数（CI）、每分钟心排血量（CO）变化情况。结果治疗组显效率高于对照组,差异有统计学意义（P〈0.05）;2组患者治疗后各项指标情况均优于治疗前,且治疗组优于对照组,差异均有统计学意义（P〈0.01和P〈0.05）。结论芪苈强心胶囊联合西药治疗CHF,能增强心肌收缩力,改善心功能,提高疗效。     

去乙酰毛花苷注射液单次静推联用芪苈强心胶囊、螺内酯片致洋地黄中毒一例

本文报道1例肾功能不全的高龄老年患者应用去乙酰毛花苷注射液(单次静推0.2 mg)联合芪苈强心胶囊、螺内酯片治疗致洋地黄中毒,地高辛血药浓度最高为4.36 ng/ml,治疗期间未使用其他洋地黄制剂,17 d后患者血药浓度仍达到2.17 ng/ml.单用1次洋地黄制剂致洋地黄中毒持续如此长时间在国内罕见报道,对于肾功能不...     

芪苈强心胶囊治疗冠心病充血性心力衰竭疗效分析

目的：观察芪苈强心胶囊对冠心病充血性心力衰竭的治疗作用。方法：39例冠心病充血性心力衰竭患者分成两组,对照组采用常规治疗,治疗组加用芪苈强心胶囊4粒,3次／d,治疗4周,观察临床症状及血流动力学变化。结果：治疗组心功能平均改善1．3级,总有效率为94．7％;对照组心功能平均改善1级,总有效率为75．0％（P〈0．05）。结论：芪苈强心胶囊能明显改善冠心病充血性心力衰竭患者的心功能。     

芪苈强心胶囊对慢性心功能不全患者左心室射血分数的影响

目的：观察芪苈强心胶囊对慢性心功能不全患者的左心室射血分数（ LVEF）的影响。方法确诊为慢性心功能不全的患者随机分为2组,对照组常规予以血管紧张素转换酶抑制剂或血管紧张素Ⅱ受体拮抗剂、B受体阻滞剂、利尿剂等治疗,治疗组在上述治疗的基础上加服芪苈强心胶囊（石家庄市以岭药业生产）3次/d,每次4粒,口服,疗程12周。每4周结束时复查1次心脏超声采集记录LVEF以及患者运动耐量进行比较。结果治疗第1个4周末LVEF无明显变化,运动耐量增加不明显。治疗第2个4周末LVEF有所增加,运动耐量有所增加。第3个4周末LVEF明显增加（ P ＜0．05）,运动耐量增加（ P ＜0．05）。结论芪苈强心胶囊能改善患者临床症状,同时能改善慢性心功能不全患者的LVEF。     

采用UPLC-Q-TOF/MS~E鉴别芪苈强心胶囊有效部位中的化学成分

为了全面快速地阐明复方中药芪苈强心胶囊的化学组成,本文利用UPLC-Q-TOF/MSE对芪苈强心胶囊进行了快速分析和成分鉴定,从芪苈强心胶囊中鉴定了40个化合物,并归属了各化合物的单味药来源。结果显示,芪苈强心胶囊的主要成分包括三萜皂苷类、黄酮苷类、C21甾类和酚酸类等。该研究比较全面地阐明了芪苈强心胶囊的化学组成,为此中药复方制剂的质量控制和物质基础研究奠定了基础。     

芪苈强心胶囊治疗慢性心功能不全患者的疗效观察

目的 观察芪苈强心胶囊对慢性心功能不全（CHF）患者左心室射血分数（LVEF）及血清B型脑钠肽（BNP）含量的影响.方法 将64例CHF患者随机分为治疗组和对照组,对照组33例予以常规治疗,包括利尿剂、血管紧张素转化酶抑制剂（ACEI/ARB）、β-受体阻滞剂等.治疗组31例在对照组的基础上给予芪苈强心胶囊1.2g口服,每天3次,连续治疗120d后检测血清BNP含量及LVEF的变化.结果 治疗后,2组LVEF均高于治疗前,BNP含量均低于治疗前,且治疗组变化幅度大于对照组,差异均有统计学意义（P〈0.05或P＜0.01）.结论 芪苈强心胶囊能明显降低CHF患者的血清BNP含量水平,升高LVEF,改善心功能,改善心室重构,改善患者症状.     

长程动态心电图对心律失常的检出率分析

目的:研究长程动态心电图对心律失常的检出率,以避免不必要的漏诊.方法:回顾性分析2017年8月1日至2019年11月30日在南昌大学第二附属医院先后行24 h动态心电图、长程动态心电图检查患者的临床资料.结果:205例中,长程动态心电图对总心律失常的检出率(91.20％)高于24 h动态心电图对总心律失常的检出率(74...     

Microcystin content of Microcystis aeruginosa is modulated by nitrogen uptake rate relative to specific growth rate or carbon fixation rate

Modulation of microcystin production has been extensively studied in both batch and continuous cultures. Positive correlations with medium nitrogen, medium phosphorous, light intensity, inorganic carbon availability, and growth rate have been reported. Negative correlations have been reported between microcystin content and medium phosphorous. The only reported quantitative relationship between any variable and microcystin production was that of growth rate. Microcystis aeruginosa PCC7806 was therefore cultured under continuous culture conditions in a bubble-lift reactor at a growth rate of 0.01 h(-1) in modified BG11 (constant phosphate concentration of 0.195 mM and varying nitrate from 0.125 to 18 mM) and sampled at steady states for analysis of cell number, microcystin content, cellular N and P, residual medium nutrient concentration, and carbon fixation rate. Cellular microcystin quotas showed significant positive correlation with both nitrate uptake and cellular nitrogen content and were negatively correlated with carbon fixation rate, phosphate uptake, and cellular phosphorous. Thus, the ratio of nitrate uptake to phosphate uptake, cellular N to cellular P, and nitrate uptake to carbon fixation were positively correlated to cellular microcystin. Microcystin quotas increased 10-fold from the lowest to the highest steady-state values. Cellular microcystin content therefore is controlled to a significant extent by variables other than growth rate, as was previously reported, with nitrogen the most significant modulator. Batch culture in BG11 under identical conditions yielded increased microcystin when nitrogen uptake exceeded relative growth rate, confirming the importance of nitrogen uptake in the modulation of microcystin content for a specific growth rate.     

Dissolution rate enhancement of gliclazide by ordered mixing

The poorly water soluble antidiabetic drug gliclazide was selected to study the effect of excipients on dissolution rate enhancement. Ordered mixtures of micronized gliclazide with lactose, mannitol, sorbitol, maltitol and sodium chloride were prepared by manual shaking of glass vials containing the drug and excipient(s). Different water soluble excipients, addition of surfactant and superdisintegrant, drug concentration and carrier particle size influenced the dissolution rate of the drug. Dissolution rate studies of the prepared ordered mixtures revealed an increase in drug dissolution with all water soluble excipients. The order of dissolution rate improvement for gliclazide was mannitol > lactose > maltitol > sorbitol > sodium chloride. Composite granules of the particle size range 355-710 μm were superior in increasing the drug dissolution rate from ordered mixtures. Reducing the carrier particle size decreased the dissolution rate of the drug as well as the increase in drug concentration. Kinetic modeling of drug release data fitted best the Hixson-Crowell model, which indicates that all the ordered mixture formulations followed the cube root law fairly well.     

Dissolution rate measurement by an automated dialysis method

An automated dialysis method for measuring the dissolution profiles of unit dose forms is described. The suitability of the method for the evaluation of these profiles has been demonstrated by an examination of tablets of sulphathiazole prepared under different conditions of pressure and excipient content. The addition of the water soluble resin, polyethylene oxide, has been shown to cause a small increase in the dissolution rates of the tablets.     

心率变异性的频谱分析

采用频谱法对比分析正常人，急性心肌梗塞和心力衰竭病人昼夜不同时间的心率变异性。结果发现正常人白天低频成份占优势，夜间高频成份相对增加，４０岁以上及６０以上两年龄组的两种频率成份显著低于４０岁以下组，心肌梗塞和心力衰竭病人两种频段的功率密度均下降，且昼夜的生理性波动减小，结论认为频谱分析能反映交感神经与迷走神经活性的高低和平衡。     

Heart rate control in hypertensive patients treated by captopril

1 The effect of captopril on autonomic reflex functions has been investigated in fifteen patients with essential hypertension by examining their responses to tests of baroreceptor function (Valsalva's manoeuvre and upright posture), sympathetic nervous system reactivity (cold pressor and mental stress tests) and parasympathetic reactivity (diving test) before and after 3 weeks' treatment with captopril. 2 Captopril significantly reduced arterial blood pressure and resting heart rate but did not affect cardiovascular responses to Valsalva's manoeuvre, upright posture, cold pressor and mental stress tests. 3 The bradycardia associated with the diving reflex test was significantly enhanced by captopril (P less than 0.01). 4 These results indicate that treatment with captopril is associated with increased parasympathetic tone but without inhibition of baroreceptor or sympathetic reflexes.     

Potentiation of the morphine-induced respiratory rate depression by captopril

The effects of morphine and captopril, an angiotensin-converting enzyme inhibitor, on respiratory frequency have been investigated in non-anesthetized mice. Morphine (10.0 mg/kg) reduced the respiratory frequency which gradually returned to the control level 2 h after the injection. The same dose of morphine when given together with captopril (0.1 and 1.0 mg/kg), caused a similar reduction in respiratory rate. This respiratory depression however, persisted until the end of the observation period. Similar results were obtained with the same dose of morphine in mice pretreated with captopril. The minimal dose of morphine reducing respiratory frequency (3.0 mg/kg), when given to the mice pretreated with captopril (0.1 mg/kg) caused a significant reduction in respiratory frequency and this effect was equal to that obtained with 10.0 mg/kg morphine alone. The results are discussed from the point of the possible inhibitory effect of captopril on the enkephalin degrading enzyme(s).     

Chromium genotoxicity as influenced by complexation and rate effects

Conclusions as to the mutagenicity and carcinogenicity of metal salts can be ambiguous and misleading, especially for metal ions having a high charge/radius ratio, hence a strong tendency to hydrolyze. Using the rec-assay, we determined whether the mutagenicity of chromium salts was reduced by complexation, as in the case of Cr(VI), or induced in the case of Cr(III). We find that several chelants, in proportion to concentration, reduce or eliminate the mutagenicity of Cr2O32-. These include EDTA, salicylate (SA), and Tiron (disodium 1,2-dihydroxylbenzene-3,5-disulfonate). Cr(III) was rendered slightly mutagenic by salicylate and citrate. None of the chelating agents or their combinations were mutagenic.     

超滤法测定喜树碱的血浆蛋白结合率

目的：测定喜树碱的血浆蛋白结合率。方法：采用超滤法结合高效液相色谱法对喜树碱与大鼠血浆以及健康人血浆蛋白结合率进行测定。结果：在1,4,8 μg·mL^-1质量浓度下喜树碱与大鼠血浆的蛋白结合率分别为（96.68±0.45）%,（96.41±0.13）%,（96.09±0.44）%;与健康人血浆的蛋白结合率分别为（95.47±0.27）%,（94.92±0.42）%,（94.72±0.48）%。结论：喜树碱与大鼠和健康人血浆蛋白均有很强的结合,并且在考察浓度范围内喜树碱的血浆蛋白结合率无浓度依赖性,但是存在种属差异。